Haloperidol Decanoate is the decanoate ester of haloperidol, a phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain leading to anti-delusionary and anti-hallucinogenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) account for its antiemetic activity.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Haloperidol Decanoate
Drug Overview
What is Haloperidol Decanoate?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Haloperidol Decanoate is a long-acting ester form of the antipsychotic haloperidol, formulated for injection into muscle as a depot product. The ester form and its oily depot formulation can differ in handling properties from the parent drug, so a documented assessment is useful.
A PDE or ADE sets a health-based limit on daily exposure to Haloperidol Decanoate from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Not necessarily. A PDE or ADE is derived for a defined route of exposure, often oral for carryover into the next product. Extrapolating to inhalation or dermal exposure needs scientific justification, so the report should state the route, scope, and assumptions behind the value.
A PDE is a health-based limit on the daily amount of Haloperidol Decanoate that could be carried over into another product and taken by patients. An OEL is a workplace airborne limit intended to protect workers over a working lifetime. They serve different purposes and use different exposure assumptions, so they are assessed separately even when drawn from the same toxicological data.
Published toxicity data can be limited for some substances. A risk-based approach can then draw on related compounds, structure-based evaluation, and the data that do exist, with each assumption documented. For potentially mutagenic compounds, ICH M7 principles may be applied where applicable.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Haloperidol Decanoate in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
Carryover is evaluated by estimating how much residue remains on shared equipment after processing Haloperidol Decanoate and could transfer into the next product. This is compared with the PDE, taking into account batch sizes, the maximum daily dose of the next product, and cleaning performance. A documented, risk-based approach under ICH Q9 principles supports the conclusion.
Yes, it can. Fine powders and dusty solids may be inhaled more easily, liquids and solutions can raise skin contact or splash considerations, and granulated or compacted material may generate less dust. The assessment should state the form of Haloperidol Decanoate considered, because the form influences likely routes of exposure and the controls that are proportionate.
Not usually. An OEB is a hazard-based category that guides handling and containment when a compound-specific OEL is not available, while an OEL is a numerical airborne limit based on a detailed review of the evidence. Where an OEL can be justified for Haloperidol Decanoate, it normally provides a more specific benchmark, and the band can still support the control strategy.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Haloperidol Decanoate to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
